ESMO 2023: aanbevolen abstracten over studies bij melanomen door oncologen en medisch specialisten

Afgelopen week was er in Madrid ESMO 2023. Hier een aantal aanbevolen abstracten door vooraanstaande oncologen gerelateerd aan melanomen.

De aanbevolen abstracten staan onder elkaar in dit artikel. Als u naar ESMO 2023 gaat kunt u via de nummers vooraf aan de titels van de abstracten deze vinden.

Aanbevolen abstracten door Dr. Alex van Akkooi:

Saturday, October 21, 2023
14:45 - 16:10 CEST; Mini oral session

Melanoma and Other Skin Tumours

1083MO - Brain metastases and survival evaluation in the SECOMBIT trial. PA Ascierto

1084MO - Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial. AM Di Giacomo

LBA50 - Three-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase III trial. S Piperno-Neumann

1086MO - Lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced mucosal melanoma after progression on immune checkpoint inhibitors (ICI): Results from the phase II C-144-01 study. E Domingo-Musibay

1087MO - A single arm phase II, multicenter trial to evaluate the clinical activity and safety of avelumab plus cetuximab in unresectable stage III or IV cutaneous squamous cell carcinoma: First results from the AliCe study. JC Becker

Monday, October 23, 2023
08:30 - 10:00 CEST; Proffered Paper Session
Melanoma and Other Skin Tumours

LBA48 - Pathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab (PEM) for resectable stage IIIb-IV melanoma from SWOG S1801. S Patel

LBA49 - mRNA-4157 (V940) individualized neoantigen therapy + pembrolizumab vs pembrolizumab in high-risk resected melanoma: Clinical efficacy and correlates of response. JS Weber

1081O - ctDNA reduction and clinical efficacy of the darovasertib + crizotinib (daro + crizo) combination in metastatic uveal melanoma (MUM). M Mckean

1082O - Concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for melanoma (MM) patients (pts) with leptomeningeal disease (LMD). IC Glitza

1085O - Atezolizumab, bevacizumab, and cobimetinib (TACo) in patients (pts) with PD1 refractory melanoma brain metastases (MBM). E Burton

ESMO 2023, aanbevolen abstracten, melanomen